MIRA PHARMACEUTICALS, INC. (MIRA) Form 10-Q — Aug 12, 2026
MIRA Pharmaceuticals reported a second-quarter 2026 net loss of $1.2 million, narrowed from $1.5 million a year earlier, bringing the six-month loss to $2.4 million versus $3.3 million in the prior-year period. The pre-revenue clinical-stage biotech spent $2.4 million of operating cash during the half, with R&D up 42% to $1.2 million while G&A fell 41% to $1.0 million. The company disclosed substantial doubt about its ability to continue as a going concern.
Key figures
- Eps
- -$0.03 (Q2 2026) vs -$0.09 (Q2 2025); -$0.06 (6M 2026) vs -$0.19 (6M 2025)
- Revenue
- 0
- Total Assets
- 8203140
- Cash Position
- 3600000
- Shares Outstanding
- 42022087
- Cash runway
- sufficient into at least Q1 2027
- Atm capacity
- 75000000
- G and a q2 2026
- 450330
- R and d q2 2026
- 705789
- Total liabilities
- 40823
- Stockholders equity
- 8162317
- Warrants outstanding
- 1763570
- Telo ownership percent
- 5%
- Stock options outstanding
- 6255575
- Nasdaq compliance deadline
- 2027-01-25
- Nasdaq deficiency notice date
- 2026-07-27
- Telo investment carrying value
- 4503973
Price after filing
1 day: +1.5%7 days: +4.3%30 days: +4.8%
Close on the filing date to close N calendar days later (from $0.74). Historical, not a forecast.
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.